Philina Lee
Direktor/Vorstandsmitglied bei FUSN PHAR
Vermögen: 3 Mio $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Philina Lee
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 33 | |
23
| Public Company | Pharmaceuticals: Major | 23 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Philina Lee
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO Chief Tech/Sci/R&D Officer Private Equity Investor Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Investor Relations Contact Director/Board Member Corporate Officer/Principal Director of Finance/CFO | |
| RELAY THERAPEUTICS, INC. | Biotechnology | Founder General Counsel Director/Board Member Chief Tech/Sci/R&D Officer | |
| Wesleyan University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal General Counsel Corporate Officer/Principal | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| IMMUNOGEN, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Director/Board Member | |
IDRx, Inc.
 IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Miscellaneous Commercial Services | Founder Founder Director/Board Member | |
MOMA Therapeutics, Inc.
 MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| The Johns Hopkins University | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Investor Private Equity Investor | |
| Yale University | College/University | Graduate Degree Doctorate Degree Undergraduate Degree | |
| ARIAD PHARMACEUTICALS, INC. | Biotechnology | President Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Masters Business Admin Graduate Degree | |
Tango Therapeutics Sub, Inc.
 Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| TANGO THERAPEUTICS, INC. | Biotechnology | Chairman Director of Finance/CFO | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Algeta US LLC
 Algeta US LLC Medical DistributorsDistribution Services Part of Bayer AG, Algeta US LLC is a pharmaceutical wholesaler. The company is based in Cambridge, MA. | Medical Distributors | Director/Board Member Director of Finance/CFO | |
| DAY ONE BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| ALBIREO PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Thrive Earlier Detection Corp.
 Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Founder | |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member Chairman | |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| NABRIVA THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Comptroller/Controller/Auditor Corporate Officer/Principal | |
| Providence College | College/University | Undergraduate Degree Undergraduate Degree | |
Aptalis Pharma LLC
 Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| OTONOMY | Biotechnology | Director/Board Member Director/Board Member | |
| ENDOCYTE, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| DNIB UNWIND INC | Biotechnology | Chairman Director/Board Member | |
| TRANSLATE BIO, INC. | Biotechnology | Chairman Director/Board Member | |
| University of Virginia Darden School of Business | College/University | Masters Business Admin Masters Business Admin | |
| University of Michigan | College/University | Undergraduate Degree Doctorate Degree | |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Founder | |
| Boston University | College/University | Undergraduate Degree Graduate Degree | |
| XILIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| VOR BIOPHARMA INC. | Biotechnology | Director/Board Member Director/Board Member | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Celsius Therapeutics, Inc.
 Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Founder | |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| The University of Chicago | College/University | Undergraduate Degree Graduate Degree | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistik
International
| Vereinigte Staaten | 45 |
| Irland | 2 |
| Kanada | 2 |
| Israel | 2 |
| Japan | 2 |
Sektoral
| Health Technology | 34 |
| Consumer Services | 11 |
| Commercial Services | 4 |
| Finance | 3 |
| Distribution Services | 2 |
Operativ
| Director/Board Member | 256 |
| Corporate Officer/Principal | 124 |
| Independent Dir/Board Member | 113 |
| Chairman | 47 |
| Undergraduate Degree | 44 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Johan Rutger Christenson | 35 |
| Heather Elizabeth Preston | 34 |
| Daniel Lynch | 32 |
| Charles Rowland | 25 |
| Alexis Borisy | 25 |
| Pablo Cagnoni | 24 |
| Barbara Duncan | 22 |
| David Meek | 19 |
| Thilo Schroeder | 18 |
| Mark Goldberg | 17 |
| Lynn Seely | 16 |
| Christoph S. Lengauer | 16 |
| Steven Gannon | 14 |
| Jeffrey Albers | 14 |
- Börse
- Insiders
- Philina Lee
- Unternehmensverbindungen
